194 related articles for article (PubMed ID: 33131514)
1. [Programmed Death-1 Inhibitors-induced Bullous Pemphigoid in 21 Cases].
Li S; He C; Zuo Y; Jin H
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2020 Oct; 42(5):603-609. PubMed ID: 33131514
[TBL] [Abstract][Full Text] [Related]
2. Lichen planus-like lesion preceding bullous pemphigoid development after programmed cell death protein-1 inhibitor treatment.
Sugawara A; Koga H; Abe T; Ishii N; Nakama T
J Dermatol; 2021 Mar; 48(3):401-404. PubMed ID: 33184934
[TBL] [Abstract][Full Text] [Related]
3. A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors.
Lopez AT; Khanna T; Antonov N; Audrey-Bayan C; Geskin L
Int J Dermatol; 2018 Jun; 57(6):664-669. PubMed ID: 29630716
[TBL] [Abstract][Full Text] [Related]
4. Retrospective Analysis of Checkpoint Inhibitor Therapy-Associated Cases of Bullous Pemphigoid From Six German Dermatology Centers.
Sadik CD; Langan EA; Gutzmer R; Fleischer MI; Loquai C; Reinhardt L; Meier F; Göppner D; Herbst RA; Zillikens D; Terheyden P
Front Immunol; 2020; 11():588582. PubMed ID: 33708189
[TBL] [Abstract][Full Text] [Related]
5. Bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors. Eight cases with clinical and immunological characterization.
García-Díez I; Ivars-Lleó M; López-Aventín D; Ishii N; Hashimoto T; Iranzo P; Pujol RM; España A; Herrero-Gonzalez JE
Int J Dermatol; 2018 Jul; 57(7):810-816. PubMed ID: 29682739
[TBL] [Abstract][Full Text] [Related]
6. Association of Bullous Pemphigoid With Immune Checkpoint Inhibitor Therapy in Patients With Cancer: A Systematic Review.
Asdourian MS; Shah N; Jacoby TV; Reynolds KL; Chen ST
JAMA Dermatol; 2022 Aug; 158(8):933-941. PubMed ID: 35612829
[TBL] [Abstract][Full Text] [Related]
7. Clinical and Immunological Profiles of 14 Patients With Bullous Pemphigoid Without IgG Autoantibodies to the BP180 NC16A Domain.
Nakama K; Koga H; Ishii N; Ohata C; Hashimoto T; Nakama T
JAMA Dermatol; 2018 Mar; 154(3):347-350. PubMed ID: 29299596
[TBL] [Abstract][Full Text] [Related]
8. A case report of steroid-refractory bullous pemphigoid induced by immune checkpoint inhibitor therapy.
Guan S; Zhang L; Zhang J; Song W; Zhong D
Front Immunol; 2022; 13():1068978. PubMed ID: 36685586
[TBL] [Abstract][Full Text] [Related]
9. Analysis of the clinical characteristics of pembrolizumab-induced bullous pemphigoid.
Wang J; Hu X; Jiang W; Zhou W; Tang M; Wu C; Liu W; Zuo X
Front Oncol; 2023; 13():1095694. PubMed ID: 36937423
[TBL] [Abstract][Full Text] [Related]
10. Checkpoint Inhibition May Trigger the Rare Variant of Anti-LAD-1 IgG-Positive, Anti-BP180 NC16A IgG-Negative Bullous Pemphigoid.
Sadik CD; Langan EA; Grätz V; Zillikens D; Terheyden P
Front Immunol; 2019; 10():1934. PubMed ID: 31474998
[TBL] [Abstract][Full Text] [Related]
11. Anti-PD1 immune checkpoint inhibitor-induced bullous pemphigoid in metastatic melanoma and non-small cell lung cancer.
Schwartzman G; Simpson MM; Jones R; Schiavone K; Coffman M; Meyerle J
Cutis; 2020 Jun; 105(6):E9-E12. PubMed ID: 32716997
[TBL] [Abstract][Full Text] [Related]
12. Bullous dermatoses secondary to anti-PD-L1 agents: a case report and review of the literature.
Kosche C; Owen JL; Sadowsky LM; Choi JN
Dermatol Online J; 2019 Oct; 25(10):. PubMed ID: 31735006
[TBL] [Abstract][Full Text] [Related]
13. Cutaneous metastases at the sites of pembrolizumab-induced bullous pemphigoid lesions in a patient with melanoma.
Ványai B; Chien YC; Beke L; Szabó IL; Péter Z; Steuer-Hajdu K; Várvölgyi T; Méhes G; Emri G
Immunotherapy; 2022 Dec; 14(17):1377-1382. PubMed ID: 36475303
[TBL] [Abstract][Full Text] [Related]
14. Decrease in eosinophils infiltrating into the skin of patients with dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid.
Chijiwa C; Takeoka S; Kamata M; Tateishi M; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Watanabe S; Tada Y
J Dermatol; 2018 May; 45(5):596-599. PubMed ID: 29411416
[TBL] [Abstract][Full Text] [Related]
15. Dupilumab for the treatment of nivolumab-induced bullous pemphigoid: a case report and review of the literature.
Klepper EM; Robinson HN
Dermatol Online J; 2021 Sep; 27(9):. PubMed ID: 34755978
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the Clinical Characteristics of Dipeptidyl Peptidase-4 Inhibitor-Induced Bullous Pemphigoid.
Sun L; Wang C; Wu C; Zhou Y; Wang C
Ann Pharmacother; 2022 Feb; 56(2):205-212. PubMed ID: 34105395
[TBL] [Abstract][Full Text] [Related]
17. Urticarial Lesions in a Pregnant Woman.
Santos-Alarcón S; Benavente-Villegas C; García-Briz I; Moneva-Léniz M; Sanchis-Sánchez C; Mateu-Puchades A
Acta Dermatovenerol Croat; 2018 Apr; 26(1):71-72. PubMed ID: 29782306
[TBL] [Abstract][Full Text] [Related]
18. Clinical characterization, treatment, and outcome of nivolumab-induced bullous pemphigoid.
Liu M; Yuan M; Sun W; Li Z; Zhou X; Wang C
Invest New Drugs; 2023 Dec; 41(6):802-807. PubMed ID: 37773473
[TBL] [Abstract][Full Text] [Related]
19. [Pemphigoid gestationis: a study of 20 cases].
Mokni M; Fourati M; Karoui I; El Euch D; Cherif F; Ben Tekaya N; Azaiz MI; Haouat S; Boubaker MS; Ben Osman Dhahri A
Ann Dermatol Venereol; 2004 Nov; 131(11):953-6. PubMed ID: 15602381
[TBL] [Abstract][Full Text] [Related]
20. Case Report: A Rare Case of Pembrolizumab-Induced Bullous Pemphigoid.
Zhang X; Sui D; Wang D; Zhang L; Wang R
Front Immunol; 2021; 12():731774. PubMed ID: 34594337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
